{"gene":"BCR","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":1987,"finding":"The normal BCR gene encodes a 160,000-dalton phosphoprotein (designated PHL) with associated serine/threonine kinase activity, as demonstrated by expression studies and kinase assays in leukemic cells.","method":"Protein expression analysis and in vitro kinase assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro kinase assay with biochemical characterization of the purified protein product, single lab but multiple orthogonal methods","pmids":["3299055"],"is_preprint":false},{"year":1987,"finding":"The BCR gene on chromosome 22 is fused in a head-to-tail fashion to the ABL oncogene as a consequence of the Philadelphia translocation, generating a chimeric BCR/ABL mRNA with 5' BCR and 3' ABL sequences that encodes an abnormal fusion protein.","method":"Molecular cloning, Southern blot, chimeric mRNA characterization","journal":"Bailliere's clinical haematology","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated across multiple labs using molecular cloning and transcript analysis; foundational structural finding about BCR-ABL fusion","pmids":["3332859","3859408"],"is_preprint":false},{"year":1988,"finding":"The BCR gene encodes a protein of 1271 amino acids; its transcripts (7.0 and 4.5 kb) are expressed in all cell types examined, and the first 902–927 amino acids of BCR are included within the CML-specific BCR-ABL chimeric mRNA.","method":"cDNA cloning, Northern blot, sequence analysis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — cDNA cloning with full sequence characterization and transcript analysis; replicated by multiple groups","pmids":["3285291"],"is_preprint":false},{"year":1990,"finding":"Both normal BCR protein products and the p210 BCR-ABL fusion protein are recovered predominantly from the cytosolic fraction, not the membrane fraction, as shown by subcellular fractionation and in vivo labeling experiments.","method":"Subcellular fractionation, in vivo radiolabeling, immunoprecipitation","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct subcellular fractionation with in vivo labeling; single lab but two orthogonal methods","pmids":["2232885"],"is_preprint":false},{"year":1987,"finding":"The P210 BCR-ABL protein does not transform NIH/3T3 fibroblasts (unlike v-abl), but a gag-BCR-ABL recombinant that adds myristylation-dependent membrane localization does transform fibroblasts, indicating that a membrane-targeting signal is required for fibroblast transformation by BCR-ABL.","method":"NIH/3T3 transformation assay, retroviral expression of BCR-ABL cDNA constructs","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct functional transformation assay with defined constructs, mechanistically informative negative result for BCR-ABL and positive result for gag-BCR-ABL","pmids":["2440107"],"is_preprint":false},{"year":1985,"finding":"BCR rearrangement and joint translocation of BCR and c-ABL sequences occur even in Ph1-negative CML patients, demonstrating that BCR-ABL fusion is the essential molecular event in CML regardless of Philadelphia chromosome visibility.","method":"Southern blot, molecular analysis of chromosomal rearrangements","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct molecular analysis demonstrating BCR-ABL rearrangement in Ph1-negative CML; confirmed independently","pmids":["3859408"],"is_preprint":false},{"year":2002,"finding":"BCR acts as a negative regulator of the BCR-ABL oncoprotein: the BCR coiled-coil domain at its amino-terminus drives oligomerization (tetramerization) of BCR-ABL, which activates ABL tyrosine kinase. BCR-ABL autophosphorylation on tyrosines inactivates the serine/threonine kinase activity of BCR. Phosphoserine-BCR binds to the ABL SH2 domain and inhibits BCR-ABL tyrosine kinase; serine 354 of BCR is critical for this inhibition.","method":"Biochemical assays, mutagenesis (serine 354), co-immunoprecipitation, kinase assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase activity assays and mutagenesis from single lab with multiple biochemical readouts","pmids":["12476302"],"is_preprint":false},{"year":2003,"finding":"Bcr is a major inhibitor of cytoplasmic c-Abl: endogenous Bcr forms a complex with c-Abl in hematopoietic and insect cells, and overexpression of Bcr suppresses activated c-Abl tyrosine kinase activity and reverses oncogenic transformation induced by an Abl SH2 construct. Bcr and the Abl SH2 protein were found in a complex, and sequestration of Bcr by Abl SH2 releases c-Abl from inhibition.","method":"Co-immunoprecipitation, kinase assays, cell transformation assays, overexpression studies","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus functional transformation and kinase assays in single lab with multiple orthogonal methods","pmids":["12543778"],"is_preprint":false},{"year":2023,"finding":"The BCR coiled-coil (CC) domain at the N-terminus controls BCR-ABL oligomerization. Molecular dynamics simulations combined with crystallography validation showed that a binary complex of the BCR CC domain serves as the basic unit; the small α1-helix forms interchain aromatic dimeric packing in binary assembly and contributes to dimer-dimer packing in the quaternary assembly, driving tetramerization essential for membrane clustering and MAPK signaling.","method":"Molecular dynamics simulations, crystallography (literature-validated), structural analysis","journal":"Protein science","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — crystallography and MD simulations from single study; structural validation referenced from experimental literature but computational modeling is primary new contribution","pmids":["36369657"],"is_preprint":false},{"year":1997,"finding":"c-CBL binds directly to the SH2 domain of BCR-ABL only when c-CBL is tyrosine-phosphorylated; however, deletion of the SH2 domain did not fully abolish CBL-BCR-ABL complex formation, suggesting a secondary interaction site or indirect bridging via CRKL. CRKL (an SH2/SH3 adapter) can mediate complex formation between c-CBL and BCR-ABL.","method":"Co-immunoprecipitation, domain deletion mapping, pulldown assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding mapped to SH2 domain with deletion mutagenesis; reciprocal Co-IP experiments; single lab","pmids":["9195915"],"is_preprint":false},{"year":2002,"finding":"BCR-ABL kinase activity (but not expression alone) is required for constitutive entry of primary myeloid CML cells into S phase independent of growth factors; the defect in growth factor-dependent cell cycle arrest is completely corrected by the ABL-specific inhibitor CGP 57148.","method":"Cell cycle analysis (flow cytometry), kinase inhibitor treatment, primary CML cell culture","journal":"British journal of haematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined cellular phenotype corrected by specific kinase inhibitor; primary cells used; single lab","pmids":["9488616"],"is_preprint":false},{"year":2002,"finding":"BCR-ABL cooperates with NUP98/HOXA9 to cause blast crisis in a murine bone marrow transplantation model; the blast crisis phenotype depends on both BCR-ABL and NUP98/HOXA9 expression. Blast crisis tumors retain sensitivity to the ABL inhibitor STI571 in vitro and in vivo, confirming continued BCR-ABL kinase dependence.","method":"Murine bone marrow transplantation model, genetic epistasis, in vitro/in vivo STI571 treatment","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in murine model with both constructs, confirmed with kinase inhibitor; functional readout with defined phenotype","pmids":["12032333"],"is_preprint":false},{"year":2002,"finding":"Bcr-Abl kinase inhibition by PD180970 blocks constitutive Stat5 DNA-binding activity and suppresses CML cell proliferation/induces apoptosis; dominant-negative Stat5 alone also induces apoptosis in K562 cells. Candidate Stat5 target genes including Bcl-x, Mcl-1, c-Myc, and cyclin D2 are downregulated after BCR-ABL kinase inhibition.","method":"Kinase inhibitor treatment, dominant-negative Stat5 expression via vaccinia virus vector, EMSA, Western blot, apoptosis assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (kinase inhibitor + dominant-negative + primary cells); single lab","pmids":["12483533"],"is_preprint":false},{"year":2008,"finding":"AHI-1 interacts with BCR-ABL and JAK2 to form an AHI-1–BCR-ABL–JAK2 protein complex in CML cells. Overexpression of AHI-1 sustains BCR-ABL and JAK2-STAT5 phosphorylation and reverses growth deficiencies from BCR-ABL down-regulation; RNAi suppression of AHI-1 reduces growth autonomy of CML stem/progenitor cells.","method":"Co-immunoprecipitation, RNAi knockdown, phosphorylation analysis, in vitro colony assays, in vivo leukemia model","journal":"Journal of Experimental Medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP identifying complex, multiple orthogonal functional methods (RNAi, overexpression, in vivo), validated in primary CML cells","pmids":["18936234"],"is_preprint":false},{"year":2011,"finding":"BCR-ABL is rapidly modified with K63-linked ubiquitin polymers upon treatment with the ubiquitin-cycle inhibitor WP1130 (which directly inhibits the deubiquitinase Usp9x), leading to BCR-ABL accumulation in aggresomes where it cannot conduct signal transduction, and inducing apoptosis in both imatinib-sensitive and -resistant CML cells.","method":"Ubiquitin linkage analysis, aggresome detection, kinase signaling assays, apoptosis assay, Usp9x deubiquitinase activity assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical characterization of ubiquitin modification type and functional consequence; single lab with multiple methods","pmids":["21248063"],"is_preprint":false},{"year":2015,"finding":"MYC and its partner MAX bind to the BCR promoter (demonstrated by ChIP) and upregulate BCR and BCR/ABL1 at both transcriptional and protein levels; silencing MYC in BCR/ABL1-positive cell lines significantly downregulates BCR and BCR/ABL1 expression, decreasing proliferation and inducing cell death.","method":"Chromatin immunoprecipitation (ChIP), MYC overexpression/silencing, luciferase reporter assay, Western blot","journal":"Molecular cancer","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP confirms direct binding, luciferase reporter validates promoter activity, functional knockdown; single lab but multiple orthogonal methods","pmids":["26179066"],"is_preprint":false},{"year":2010,"finding":"BCR and BCR/ABL1 are similarly downregulated during myeloid differentiation in healthy donors and in chronic-phase CML patients but not in blast crisis, suggesting BCR and BCR/ABL1 share a common transcriptional control mechanism that is disrupted in blast crisis (in trans deregulation of both BCR and BCR/ABL1 promoters).","method":"Gene expression analysis during myeloid differentiation, comparison across CML phases","journal":"Leukemia","confidence":"Low","confidence_rationale":"Tier 3 / Weak — expression analysis during differentiation without direct promoter or transcription factor binding experiments; single lab","pmids":["20520635"],"is_preprint":false},{"year":2006,"finding":"BCR-ABL promotes expression of histidine decarboxylase (HDC) and synthesis of histamine in CML basophilic cells via the PI3-kinase signaling pathway; BCR-ABL tyrosine kinase inhibitors (imatinib, nilotinib) decreased HDC mRNA expression and histamine levels in BCR-ABL-transformed cells and primary CML cells.","method":"BCR-ABL expression in Ba/F3 cells, PI3K pathway inhibition, RT-PCR, histamine measurement, TKI treatment","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct BCR-ABL expression and PI3K pathway inhibition experiments with functional readout; single lab with multiple methods","pmids":["16849647"],"is_preprint":false},{"year":2014,"finding":"IRF5 is expressed in CML cells where it interacts with BCR-ABL kinase, which induces IRF5 tyrosine phosphorylation and reduces its transcriptional activity; imatinib partially restores IRF5 transcriptional activity. A BCR-ABL consensus site mutant (IRF5 Y104F) still shows tyrosine phosphorylation, suggesting additional phosphorylation sites or downstream kinase involvement.","method":"Co-immunoprecipitation, phosphorylation analysis, site-directed mutagenesis (Y104F), transcriptional activity assay, imatinib treatment","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and mutagenesis with phosphorylation and functional transcription assays; single lab","pmids":["24445143"],"is_preprint":false},{"year":2010,"finding":"BCR-ABL-mediated upregulation of PRAME leads to increased EZH2 binding to the TRAIL promoter and suppression of TRAIL expression in CML cells; knockdown of PRAME or EZH2 by RNA interference restores TRAIL expression and enhances imatinib sensitivity.","method":"RNAi knockdown of PRAME and EZH2, chromatin immunoprecipitation (EZH2 on TRAIL promoter), RT-PCR, Western blot","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi combined with ChIP demonstrating mechanistic pathway; single lab with multiple methods","pmids":["20838376"],"is_preprint":false},{"year":2009,"finding":"PTEN is downregulated by BCR-ABL in leukemia stem cells in CML; PTEN deletion accelerates CML development while PTEN overexpression delays CML and B-ALL development, suppresses leukemia stem cells, and induces cell-cycle arrest. PTEN suppresses B-ALL through regulating its downstream gene Akt1.","method":"Mouse model of BCR-ABL-induced leukemia, conditional Pten deletion, PTEN overexpression, stem cell assays, cell-cycle analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function and overexpression in murine model with defined cellular phenotype and pathway placement (PTEN-Akt1 axis); single lab with multiple orthogonal approaches","pmids":["19965668"],"is_preprint":false},{"year":2011,"finding":"BCR-ABL kinase activity suppresses expression of Thanatos-associated protein 11 (THAP11) in CML cells; THAP11 inhibits c-Myc transcription and its restoration by Abl kinase inhibitors reduces c-Myc expression, cyclin D1, ODC, and increases p21Cip1, inhibiting CML cell proliferation.","method":"Abl kinase inhibitor treatment, siRNA depletion of BCR-ABL, THAP11 overexpression, colony forming assay, RT-PCR, Western blot","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional experiments (inhibitor, siRNA, overexpression) with defined molecular pathway; single lab","pmids":["21400515"],"is_preprint":false},{"year":2023,"finding":"BCR-ABL protein can be selectively degraded via the N-end rule ubiquitin-proteasome pathway using single amino acid-based PROTACs; the degradation level can be adjusted by substituting different amino acids at the N-end rule recognition site, and a single PEG linker achieves the best proteolytic effect. This results in effective growth inhibition of BCR-ABL-expressing K562 cells in vitro and in a xenograft model in vivo.","method":"PROTAC-mediated protein degradation, in vitro cell proliferation assay, K562 xenograft mouse model, Western blot","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical degradation assay with mutagenesis of N-end rule signal and in vivo validation; single lab with multiple methods","pmids":["37392851"],"is_preprint":false}],"current_model":"BCR encodes a cytosolic serine/threonine kinase whose N-terminal coiled-coil domain drives BCR-ABL oligomerization/tetramerization, thereby activating the ABL kinase; the BCR moiety is autophosphorylated on tyrosines by BCR-ABL (inactivating BCR's own kinase activity), while phosphoserine-BCR can bind back to the ABL SH2 domain and inhibit oncogenic kinase activity. BCR-ABL signals constitutively through STAT5, PI3K/AKT, RAS/MAPK, and JAK2 pathways; it forms protein complexes with partners including CBL (via SH2), CRKL, AHI-1, and JAK2; it suppresses TRAIL via PRAME/EZH2, drives histamine synthesis via PI3K/HDC, phosphorylates and inactivates IRF5, and suppresses THAP11 to upregulate c-Myc. BCR and BCR-ABL expression are both transcriptionally regulated by the MYC/MAX heterodimer binding to the BCR promoter, and BCR-ABL is subject to K63-linked ubiquitination and aggresomal sequestration that blocks its signaling."},"narrative":{"mechanistic_narrative":"BCR encodes a ubiquitously expressed 160-kDa cytosolic phosphoprotein of 1271 amino acids that carries an intrinsic serine/threonine kinase activity [PMID:3299055, PMID:3285291, PMID:2232885]. Its principal biomedical importance derives from the Philadelphia translocation, which fuses 5' BCR sequences (the first ~902–927 residues) to the 3' ABL oncogene to create the chimeric BCR-ABL mRNA and fusion oncoprotein that is the essential molecular event in chronic myeloid leukemia [PMID:3332859, PMID:3859408, PMID:3285291]. Within the fusion, the BCR moiety supplies an N-terminal coiled-coil domain that drives oligomerization and tetramerization of BCR-ABL, constitutively activating the ABL tyrosine kinase and enabling membrane clustering and downstream MAPK signaling [PMID:12476302, PMID:36369657]. Reciprocally, normal BCR is a negative regulator of ABL: it forms a complex with c-Abl and, through phosphoserine-354, binds the ABL SH2 domain to inhibit kinase activity, while BCR-ABL-mediated tyrosine autophosphorylation inactivates BCR's own serine/threonine kinase [PMID:12476302, PMID:12543778]. The oncogenic kinase rewires hematopoietic cells, driving growth-factor-independent S-phase entry [PMID:9488616] and signaling through STAT5 to sustain anti-apoptotic and proliferative targets including Bcl-x, Mcl-1, c-Myc and cyclin D2 [PMID:12483533], through PI3K (with PTEN downregulation in leukemic stem cells) [PMID:16849647, PMID:19965668], and through partner complexes with CBL, CRKL, AHI-1 and JAK2 [PMID:9195915, PMID:18936234]. Downstream transcriptional reprogramming includes PRAME/EZH2-mediated TRAIL suppression, IRF5 tyrosine phosphorylation and inactivation, and THAP11 suppression that upregulates c-Myc [PMID:24445143, PMID:20838376, PMID:21400515]. BCR-ABL expression is itself driven by MYC/MAX binding to the BCR promoter [PMID:26179066], and the oncoprotein is subject to K63-linked ubiquitination and aggresomal sequestration as well as targeted degradation strategies that abolish its signaling [PMID:21248063, PMID:37392851].","teleology":[{"year":1987,"claim":"Established that the normal BCR gene product is an enzyme, defining it as a 160-kDa phosphoprotein with intrinsic serine/threonine kinase activity rather than a passive structural protein.","evidence":"Protein expression analysis and in vitro kinase assay in leukemic cells","pmids":["3299055"],"confidence":"High","gaps":["Physiological substrates of BCR's own kinase not identified","Regulation of BCR kinase activity in normal cells unknown"]},{"year":1987,"claim":"Defined the molecular basis of CML by showing BCR is fused head-to-tail to ABL by the Philadelphia translocation, generating a chimeric mRNA and fusion protein.","evidence":"Molecular cloning, Southern blot and chimeric mRNA characterization","pmids":["3332859","3859408"],"confidence":"High","gaps":["Mechanism by which fusion activates ABL not yet defined at this stage","Functional consequence of the BCR portion unresolved"]},{"year":1988,"claim":"Provided the full protein coding sequence (1271 aa) and showed BCR is broadly expressed, while delimiting the BCR segment (first ~902–927 aa) retained in BCR-ABL.","evidence":"cDNA cloning, Northern blot and sequence analysis","pmids":["3285291"],"confidence":"High","gaps":["Domain function within the retained BCR segment not yet assigned"]},{"year":1985,"claim":"Showed BCR-ABL fusion is the essential molecular lesion in CML even when the Philadelphia chromosome is cytogenetically invisible, establishing the fusion (not the visible chromosome) as the disease driver.","evidence":"Southern blot and molecular rearrangement analysis in Ph1-negative CML","pmids":["3859408"],"confidence":"High","gaps":["Does not address how the fusion transforms cells mechanistically"]},{"year":1990,"claim":"Localized both normal BCR and p210 BCR-ABL to the cytosol, framing where the kinase activity is deployed.","evidence":"Subcellular fractionation with in vivo radiolabeling and immunoprecipitation","pmids":["2232885"],"confidence":"High","gaps":["Did not address dynamic or signal-induced membrane recruitment"]},{"year":1987,"claim":"Demonstrated that membrane targeting is rate-limiting for fibroblast transformation, since p210 BCR-ABL fails to transform NIH/3T3 cells but a myristylated gag-BCR-ABL does.","evidence":"NIH/3T3 transformation assay with defined retroviral BCR-ABL constructs","pmids":["2440107"],"confidence":"High","gaps":["Relevance of fibroblast assay to hematopoietic transformation unclear","Did not define the activating role of BCR coiled-coil oligomerization"]},{"year":2002,"claim":"Resolved the reciprocal regulatory relationship: the BCR coiled-coil drives tetramerization that activates ABL, while phosphoserine-354 BCR binds the ABL SH2 domain to inhibit the oncogenic kinase.","evidence":"Biochemical and kinase assays, Co-IP, and serine 354 mutagenesis","pmids":["12476302"],"confidence":"Medium","gaps":["Single-lab biochemistry without structural confirmation at this stage","Stoichiometry and dynamics of activation versus inhibition not quantified"]},{"year":2003,"claim":"Established normal Bcr as a major endogenous inhibitor of cytoplasmic c-Abl, with Abl SH2 sequestering Bcr to release c-Abl from inhibition.","evidence":"Co-IP, kinase and transformation assays, overexpression in hematopoietic and insect cells","pmids":["12543778"],"confidence":"Medium","gaps":["Physiological context where this regulation operates unclear","Single-lab evidence"]},{"year":2023,"claim":"Defined the structural logic of BCR coiled-coil assembly, identifying a binary unit and α1-helix aromatic packing that builds the tetramer required for membrane clustering and MAPK signaling.","evidence":"Molecular dynamics simulations with crystallographic validation and structural analysis","pmids":["36369657"],"confidence":"Medium","gaps":["Primary contribution is computational modeling","Direct functional test of individual packing residues in cells limited"]},{"year":1997,"claim":"Mapped CBL recruitment to the BCR-ABL SH2 domain (phospho-dependent) and identified CRKL as a bridging adapter, building the BCR-ABL adaptor complex.","evidence":"Co-IP, domain deletion mapping and pulldown assays","pmids":["9195915"],"confidence":"Medium","gaps":["Secondary CBL interaction site not identified","Functional output of the complex not measured here"]},{"year":1998,"claim":"Showed BCR-ABL kinase activity, not mere expression, drives growth-factor-independent S-phase entry, confirming kinase function as the proliferative driver.","evidence":"Cell cycle flow cytometry with ABL inhibitor CGP 57148 in primary CML cells","pmids":["9488616"],"confidence":"Medium","gaps":["Downstream effectors linking kinase to cell-cycle machinery not defined here"]},{"year":2002,"claim":"Connected BCR-ABL kinase to constitutive STAT5 activation and identified anti-apoptotic/proliferative STAT5 targets, defining a core survival pathway.","evidence":"Kinase inhibitor and dominant-negative Stat5 expression, EMSA, apoptosis assays in K562","pmids":["12483533"],"confidence":"Medium","gaps":["Direct versus indirect regulation of named targets not fully separated","Single-lab data"]},{"year":2002,"claim":"Demonstrated genetic cooperation between BCR-ABL and NUP98/HOXA9 in driving blast crisis while preserving BCR-ABL kinase dependence.","evidence":"Murine bone marrow transplantation with genetic epistasis and STI571 treatment","pmids":["12032333"],"confidence":"High","gaps":["Molecular mechanism of cooperation between the two oncogenes not resolved"]},{"year":2006,"claim":"Identified a PI3K-dependent BCR-ABL output driving histidine decarboxylase expression and histamine synthesis in basophilic CML cells.","evidence":"BCR-ABL expression in Ba/F3, PI3K inhibition, RT-PCR, histamine measurement, TKI treatment","pmids":["16849647"],"confidence":"Medium","gaps":["Transcription factors linking PI3K to HDC not defined","Single-lab evidence"]},{"year":2008,"claim":"Identified AHI-1 as a scaffold forming an AHI-1–BCR-ABL–JAK2 complex that sustains BCR-ABL/JAK2-STAT5 phosphorylation and growth autonomy of CML stem/progenitor cells.","evidence":"Reciprocal Co-IP, RNAi, overexpression, colony assays and in vivo leukemia model","pmids":["18936234"],"confidence":"High","gaps":["Structural basis of the ternary complex unknown","Whether AHI-1 acts on normal BCR not addressed"]},{"year":2009,"claim":"Placed BCR-ABL upstream of PTEN downregulation in leukemic stem cells, with PTEN acting via Akt1 to restrain leukemogenesis.","evidence":"Murine BCR-ABL leukemia model with conditional Pten deletion/overexpression and stem cell assays","pmids":["19965668"],"confidence":"High","gaps":["Mechanism by which BCR-ABL represses PTEN not defined"]},{"year":2010,"claim":"Suggested BCR and BCR/ABL1 share a common transcriptional control that is downregulated during normal myeloid differentiation but deregulated in trans in blast crisis.","evidence":"Gene expression analysis across myeloid differentiation and CML phases","pmids":["20520635"],"confidence":"Low","gaps":["No direct promoter or transcription factor binding experiments","Correlative expression data only","Single lab"]},{"year":2010,"claim":"Defined a BCR-ABL–PRAME–EZH2 axis that epigenetically suppresses TRAIL, linking the oncogene to apoptosis resistance.","evidence":"RNAi of PRAME/EZH2, ChIP of EZH2 on TRAIL promoter, RT-PCR/Western","pmids":["20838376"],"confidence":"Medium","gaps":["Mechanism of PRAME upregulation by BCR-ABL unresolved"]},{"year":2011,"claim":"Showed K63-linked ubiquitination (via Usp9x inhibition) drives BCR-ABL into aggresomes where it cannot signal, identifying a degradative vulnerability independent of imatinib resistance status.","evidence":"Ubiquitin linkage and aggresome analysis, signaling and apoptosis assays with WP1130","pmids":["21248063"],"confidence":"Medium","gaps":["Endogenous E3 ligase mediating K63 modification not identified","Single-lab evidence"]},{"year":2011,"claim":"Established that BCR-ABL kinase suppresses THAP11 to relieve repression of c-Myc, driving proliferation via c-Myc/cyclin D1/ODC and reduced p21.","evidence":"Abl inhibitor, BCR-ABL siRNA, THAP11 overexpression, colony assays, RT-PCR/Western","pmids":["21400515"],"confidence":"Medium","gaps":["How kinase activity represses THAP11 not defined","Single-lab evidence"]},{"year":2014,"claim":"Showed BCR-ABL interacts with and tyrosine-phosphorylates IRF5 to reduce its transcriptional activity, with a Y104F mutant implying additional phosphosites.","evidence":"Co-IP, phosphorylation analysis, Y104F mutagenesis, transcription assays, imatinib treatment","pmids":["24445143"],"confidence":"Medium","gaps":["Additional phosphorylation sites not mapped","Functional consequence of IRF5 inactivation in CML pathology incompletely defined"]},{"year":2015,"claim":"Identified MYC/MAX as direct transcriptional drivers of BCR and BCR/ABL1 via promoter binding, creating a feed-forward loop with c-Myc as both upstream and downstream of the oncogene.","evidence":"ChIP, MYC overexpression/silencing, luciferase reporter, Western blot","pmids":["26179066"],"confidence":"High","gaps":["Interplay with the proposed differentiation-linked control not integrated"]},{"year":2023,"claim":"Demonstrated that BCR-ABL can be selectively eliminated via N-end rule ubiquitin-proteasome PROTACs, providing a tunable degradation strategy with in vivo efficacy.","evidence":"Single amino acid PROTACs with N-end rule mutagenesis, proliferation assays, K562 xenograft","pmids":["37392851"],"confidence":"Medium","gaps":["Selectivity over normal BCR not fully established","Single-lab proof of concept"]},{"year":null,"claim":"The physiological function and substrates of normal BCR's serine/threonine kinase, and how its inhibitory regulation of c-Abl operates in healthy cells, remain undefined relative to the well-characterized oncogenic fusion.","evidence":"","pmids":[],"confidence":"Low","gaps":["No physiological BCR kinase substrate identified","Normal cellular role of BCR distinct from its fusion partner role unclear","Structure of full-length BCR not determined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,6,18]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,6]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[6,7]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[12,13,17]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[12,13,17,8]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,5,11]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[10,20]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[15,18,19,21]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[14,22]}],"complexes":[],"partners":["ABL1","CBL","CRKL","AHI1","JAK2","IRF5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P11274","full_name":"Breakpoint cluster region protein","aliases":["Renal carcinoma antigen NY-REN-26"],"length_aa":1271,"mass_kda":142.8,"function":"Protein with a unique structure having two opposing regulatory activities toward small GTP-binding proteins. The C-terminus is a GTPase-activating protein (GAP) domain which stimulates GTP hydrolysis by RAC1, RAC2 and CDC42. Accelerates the intrinsic rate of GTP hydrolysis of RAC1 or CDC42, leading to down-regulation of the active GTP-bound form (PubMed:17116687, PubMed:1903516, PubMed:7479768). The central Dbl homology (DH) domain functions as guanine nucleotide exchange factor (GEF) that modulates the GTPases CDC42, RHOA and RAC1. Promotes the conversion of CDC42, RHOA and RAC1 from the GDP-bound to the GTP-bound form (PubMed:23940119, PubMed:7479768). The amino terminus contains an intrinsic kinase activity (PubMed:1657398). Functions as an important negative regulator of neuronal RAC1 activity (By similarity). Regulates macrophage functions such as CSF1-directed motility and phagocytosis through the modulation of RAC1 activity (PubMed:17116687). Plays a major role as a RHOA GEF in keratinocytes being involved in focal adhesion formation and keratinocyte differentiation (PubMed:23940119)","subcellular_location":"Postsynaptic density; Cell projection, dendritic spine; Cell projection, axon; Synapse","url":"https://www.uniprot.org/uniprotkb/P11274/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCR","classification":"Not Classified","n_dependent_lines":9,"n_total_lines":1208,"dependency_fraction":0.0074503311258278145},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CSNK2B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/BCR","total_profiled":1310},"omim":[{"mim_id":"621096","title":"IMMUNODEFICIENCY 132B; IMD132B","url":"https://www.omim.org/entry/621096"},{"mim_id":"621068","title":"NEURODEVELOPMENTAL DISORDER WITH HYPOTONIA, POOR GROWTH, DYSMORPHIC FACIES, AND AGAMMAGLOBULINEMIA; NEDHGFA","url":"https://www.omim.org/entry/621068"},{"mim_id":"620440","title":"GRB2-BINDING ADAPTOR PROTEIN, TRANSMEMBRANE; GAPT","url":"https://www.omim.org/entry/620440"},{"mim_id":"620430","title":"AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 3; ADMIO3","url":"https://www.omim.org/entry/620430"},{"mim_id":"619693","title":"AGAMMAGLOBULINEMIA 9, AUTOSOMAL RECESSIVE; AGM9","url":"https://www.omim.org/entry/619693"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BCR"},"hgnc":{"alias_symbol":["D22S662","CML","PHL","ALL"],"prev_symbol":["D22S11","BCR1"]},"alphafold":{"accession":"P11274","domains":[{"cath_id":"4.10.280.30","chopping":"5-55","consensus_level":"medium","plddt":78.6733,"start":5,"end":55},{"cath_id":"1.20.900.10","chopping":"493-696","consensus_level":"high","plddt":83.5628,"start":493,"end":696},{"cath_id":"2.30.29.30","chopping":"702-769_835-870","consensus_level":"medium","plddt":83.2145,"start":702,"end":870},{"cath_id":"2.60.40.150","chopping":"910-982_995-1039","consensus_level":"medium","plddt":84.6744,"start":910,"end":1039},{"cath_id":"1.10.555.10","chopping":"1057-1217_1234-1252","consensus_level":"high","plddt":89.485,"start":1057,"end":1252}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11274","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11274-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11274-F1-predicted_aligned_error_v6.png","plddt_mean":64.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCR","jax_strain_url":"https://www.jax.org/strain/search?query=BCR"},"sequence":{"accession":"P11274","fasta_url":"https://rest.uniprot.org/uniprotkb/P11274.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11274/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11274"}},"corpus_meta":[{"pmid":"19064740","id":"PMC_19064740","title":"Translation of the Philadelphia chromosome into therapy for CML.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19064740","citation_count":516,"is_preprint":false},{"pmid":"14982876","id":"PMC_14982876","title":"The biology of CML blast crisis.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14982876","citation_count":423,"is_preprint":false},{"pmid":"16557260","id":"PMC_16557260","title":"ITAM-mediated tonic signalling through pre-BCR and BCR complexes.","date":"2006","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16557260","citation_count":236,"is_preprint":false},{"pmid":"23883968","id":"PMC_23883968","title":"New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.","date":"2013","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23883968","citation_count":235,"is_preprint":false},{"pmid":"22156549","id":"PMC_22156549","title":"Molecular pathways: BCR-ABL.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/22156549","citation_count":200,"is_preprint":false},{"pmid":"25525119","id":"PMC_25525119","title":"Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25525119","citation_count":198,"is_preprint":false},{"pmid":"3859408","id":"PMC_3859408","title":"C-abl and bcr are rearranged in a Ph1-negative CML patient.","date":"1985","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/3859408","citation_count":182,"is_preprint":false},{"pmid":"23223358","id":"PMC_23223358","title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23223358","citation_count":179,"is_preprint":false},{"pmid":"25814077","id":"PMC_25814077","title":"Natural course and biology of CML.","date":"2015","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/25814077","citation_count":172,"is_preprint":false},{"pmid":"12032333","id":"PMC_12032333","title":"A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12032333","citation_count":161,"is_preprint":false},{"pmid":"11423669","id":"PMC_11423669","title":"STI571: targeting BCR-ABL as therapy for CML.","date":"2001","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/11423669","citation_count":159,"is_preprint":false},{"pmid":"2440107","id":"PMC_2440107","title":"The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts.","date":"1987","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2440107","citation_count":150,"is_preprint":false},{"pmid":"28331056","id":"PMC_28331056","title":"Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28331056","citation_count":113,"is_preprint":false},{"pmid":"12483533","id":"PMC_12483533","title":"Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12483533","citation_count":108,"is_preprint":false},{"pmid":"21248063","id":"PMC_21248063","title":"Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21248063","citation_count":106,"is_preprint":false},{"pmid":"21693757","id":"PMC_21693757","title":"Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21693757","citation_count":105,"is_preprint":false},{"pmid":"19965668","id":"PMC_19965668","title":"PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19965668","citation_count":103,"is_preprint":false},{"pmid":"8613635","id":"PMC_8613635","title":"Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5).","date":"1996","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8613635","citation_count":98,"is_preprint":false},{"pmid":"19959081","id":"PMC_19959081","title":"Epidemiology of chronic myeloid leukaemia (CML).","date":"2009","source":"Best practice & research. Clinical haematology","url":"https://pubmed.ncbi.nlm.nih.gov/19959081","citation_count":97,"is_preprint":false},{"pmid":"16213151","id":"PMC_16213151","title":"Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).","date":"2005","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/16213151","citation_count":94,"is_preprint":false},{"pmid":"16278304","id":"PMC_16278304","title":"Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16278304","citation_count":90,"is_preprint":false},{"pmid":"21195477","id":"PMC_21195477","title":"Regulation of BCR signaling.","date":"2010","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21195477","citation_count":87,"is_preprint":false},{"pmid":"3285291","id":"PMC_3285291","title":"bcr genes and transcripts.","date":"1988","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/3285291","citation_count":86,"is_preprint":false},{"pmid":"3299055","id":"PMC_3299055","title":"Evidence that the phl gene encodes a 160,000-dalton phosphoprotein with associated kinase activity.","date":"1987","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3299055","citation_count":85,"is_preprint":false},{"pmid":"24216514","id":"PMC_24216514","title":"A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCR(-) B cells.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24216514","citation_count":81,"is_preprint":false},{"pmid":"24705490","id":"PMC_24705490","title":"Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24705490","citation_count":81,"is_preprint":false},{"pmid":"18024655","id":"PMC_18024655","title":"The Biology of CML blast crisis.","date":"2007","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/18024655","citation_count":70,"is_preprint":false},{"pmid":"28172415","id":"PMC_28172415","title":"BASIC: BCR assembly from single cells.","date":"2017","source":"Bioinformatics (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/28172415","citation_count":69,"is_preprint":false},{"pmid":"18653275","id":"PMC_18653275","title":"Imatinib resistance in CML.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/18653275","citation_count":66,"is_preprint":false},{"pmid":"28135254","id":"PMC_28135254","title":"The IgM receptor FcμR limits tonic BCR signaling by regulating expression of the IgM BCR.","date":"2017","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28135254","citation_count":66,"is_preprint":false},{"pmid":"3670297","id":"PMC_3670297","title":"Expression of bcr and bcr-abl fusion transcripts in normal and leukemic cells.","date":"1987","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3670297","citation_count":65,"is_preprint":false},{"pmid":"16572205","id":"PMC_16572205","title":"BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.","date":"2006","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/16572205","citation_count":65,"is_preprint":false},{"pmid":"9195915","id":"PMC_9195915","title":"Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9195915","citation_count":63,"is_preprint":false},{"pmid":"8980609","id":"PMC_8980609","title":"Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?","date":"1997","source":"Acta haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/8980609","citation_count":63,"is_preprint":false},{"pmid":"22210880","id":"PMC_22210880","title":"How I treat childhood CML.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22210880","citation_count":61,"is_preprint":false},{"pmid":"18936234","id":"PMC_18936234","title":"AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.","date":"2008","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18936234","citation_count":60,"is_preprint":false},{"pmid":"27839570","id":"PMC_27839570","title":"Management of CML-blast crisis.","date":"2016","source":"Best practice & research. Clinical haematology","url":"https://pubmed.ncbi.nlm.nih.gov/27839570","citation_count":58,"is_preprint":false},{"pmid":"35933523","id":"PMC_35933523","title":"Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.","date":"2022","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/35933523","citation_count":53,"is_preprint":false},{"pmid":"2232885","id":"PMC_2232885","title":"BCR-ABL and BCR proteins: biochemical characterization and localization.","date":"1990","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/2232885","citation_count":50,"is_preprint":false},{"pmid":"19959094","id":"PMC_19959094","title":"CML in pregnancy and childhood.","date":"2009","source":"Best practice & research. Clinical haematology","url":"https://pubmed.ncbi.nlm.nih.gov/19959094","citation_count":49,"is_preprint":false},{"pmid":"25814086","id":"PMC_25814086","title":"The interferon-alpha revival in CML.","date":"2015","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/25814086","citation_count":48,"is_preprint":false},{"pmid":"20838376","id":"PMC_20838376","title":"BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20838376","citation_count":48,"is_preprint":false},{"pmid":"12901289","id":"PMC_12901289","title":"STI571 as a targeted therapy for CML.","date":"2003","source":"Cancer investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12901289","citation_count":44,"is_preprint":false},{"pmid":"21157035","id":"PMC_21157035","title":"BCR-ABL kinase is dead; long live the CML stem cell.","date":"2010","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/21157035","citation_count":44,"is_preprint":false},{"pmid":"22912393","id":"PMC_22912393","title":"Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients.","date":"2012","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/22912393","citation_count":44,"is_preprint":false},{"pmid":"34659899","id":"PMC_34659899","title":"Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations.","date":"2021","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34659899","citation_count":39,"is_preprint":false},{"pmid":"25501124","id":"PMC_25501124","title":"Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25501124","citation_count":39,"is_preprint":false},{"pmid":"26179066","id":"PMC_26179066","title":"BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.","date":"2015","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26179066","citation_count":37,"is_preprint":false},{"pmid":"26585806","id":"PMC_26585806","title":"Is there a best TKI for chronic phase CML?","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26585806","citation_count":36,"is_preprint":false},{"pmid":"24629639","id":"PMC_24629639","title":"ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.","date":"2014","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24629639","citation_count":36,"is_preprint":false},{"pmid":"34007045","id":"PMC_34007045","title":"Small-molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance.","date":"2021","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/34007045","citation_count":34,"is_preprint":false},{"pmid":"9488616","id":"PMC_9488616","title":"Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors.","date":"1998","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/9488616","citation_count":34,"is_preprint":false},{"pmid":"21074890","id":"PMC_21074890","title":"Syk mediates BCR- and CD40-signaling integration during B cell activation.","date":"2010","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/21074890","citation_count":33,"is_preprint":false},{"pmid":"20520635","id":"PMC_20520635","title":"BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.","date":"2010","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/20520635","citation_count":33,"is_preprint":false},{"pmid":"9178724","id":"PMC_9178724","title":"Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone?","date":"1997","source":"The Journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9178724","citation_count":33,"is_preprint":false},{"pmid":"30504305","id":"PMC_30504305","title":"The argument for using imatinib in CML.","date":"2018","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/30504305","citation_count":32,"is_preprint":false},{"pmid":"3332859","id":"PMC_3332859","title":"The BCR/ABL hybrid gene.","date":"1987","source":"Bailliere's clinical haematology","url":"https://pubmed.ncbi.nlm.nih.gov/3332859","citation_count":31,"is_preprint":false},{"pmid":"28457753","id":"PMC_28457753","title":"Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications.","date":"2017","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/28457753","citation_count":31,"is_preprint":false},{"pmid":"18024653","id":"PMC_18024653","title":"Medical management of CML.","date":"2007","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/18024653","citation_count":31,"is_preprint":false},{"pmid":"37392851","id":"PMC_37392851","title":"Single amino acid-based PROTACs trigger degradation of the oncogenic kinase BCR-ABL in chronic myeloid leukemia (CML).","date":"2023","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37392851","citation_count":31,"is_preprint":false},{"pmid":"24967705","id":"PMC_24967705","title":"ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.","date":"2014","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24967705","citation_count":31,"is_preprint":false},{"pmid":"2733454","id":"PMC_2733454","title":"No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.","date":"1989","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/2733454","citation_count":31,"is_preprint":false},{"pmid":"33207600","id":"PMC_33207600","title":"The New ELN Recommendations for Treating CML.","date":"2020","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33207600","citation_count":29,"is_preprint":false},{"pmid":"10024226","id":"PMC_10024226","title":"Mapping of T-cell epitopes of Phl p 5: evidence for crossreacting and non-crossreacting T-cell epitopes within Phl p 5 isoallergens.","date":"1998","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10024226","citation_count":29,"is_preprint":false},{"pmid":"10232368","id":"PMC_10232368","title":"Cell biology of CML cells.","date":"1999","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/10232368","citation_count":28,"is_preprint":false},{"pmid":"30504307","id":"PMC_30504307","title":"We do still transplant CML, don't we?","date":"2018","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/30504307","citation_count":27,"is_preprint":false},{"pmid":"16931624","id":"PMC_16931624","title":"BCR ubiquitination controls BCR-mediated antigen processing and presentation.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16931624","citation_count":27,"is_preprint":false},{"pmid":"31273251","id":"PMC_31273251","title":"MicroRNA signature refine response prediction in CML.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31273251","citation_count":27,"is_preprint":false},{"pmid":"3332858","id":"PMC_3332858","title":"Chromosome abnormalities in CML.","date":"1987","source":"Bailliere's clinical haematology","url":"https://pubmed.ncbi.nlm.nih.gov/3332858","citation_count":26,"is_preprint":false},{"pmid":"28972424","id":"PMC_28972424","title":"First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.","date":"2017","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/28972424","citation_count":26,"is_preprint":false},{"pmid":"22526205","id":"PMC_22526205","title":"Detection of Phl p 1, Phl p 5, Phl p 7 and Phl p 12 specific IgE antibodies in the sera of children and adult patients allergic to Phleum pollen.","date":"2012","source":"Allergology international : official journal of the Japanese Society of Allergology","url":"https://pubmed.ncbi.nlm.nih.gov/22526205","citation_count":26,"is_preprint":false},{"pmid":"21637917","id":"PMC_21637917","title":"BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.","date":"2011","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21637917","citation_count":26,"is_preprint":false},{"pmid":"18638369","id":"PMC_18638369","title":"FISH mapping of Philadelphia negative BCR/ABL1 positive CML.","date":"2008","source":"Molecular cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/18638369","citation_count":26,"is_preprint":false},{"pmid":"25170113","id":"PMC_25170113","title":"Targeting the JAK2-STAT5 pathway in CML.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25170113","citation_count":26,"is_preprint":false},{"pmid":"24445143","id":"PMC_24445143","title":"IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.","date":"2014","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24445143","citation_count":25,"is_preprint":false},{"pmid":"15749869","id":"PMC_15749869","title":"B cell receptor (BCR) cross-talk: CD40 engagement enhances BCR-induced ERK activation.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15749869","citation_count":24,"is_preprint":false},{"pmid":"17006667","id":"PMC_17006667","title":"Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.","date":"2006","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/17006667","citation_count":24,"is_preprint":false},{"pmid":"21400515","id":"PMC_21400515","title":"Down-regulation of Thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression.","date":"2011","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21400515","citation_count":24,"is_preprint":false},{"pmid":"20432440","id":"PMC_20432440","title":"Dysregulated calcium homeostasis and oxidative stress in chronic myeloid leukemia (CML) cells.","date":"2010","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20432440","citation_count":24,"is_preprint":false},{"pmid":"20008231","id":"PMC_20008231","title":"Initial treatment for patients with CML.","date":"2009","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/20008231","citation_count":23,"is_preprint":false},{"pmid":"33283168","id":"PMC_33283168","title":"Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice.","date":"2020","source":"HemaSphere","url":"https://pubmed.ncbi.nlm.nih.gov/33283168","citation_count":23,"is_preprint":false},{"pmid":"29222245","id":"PMC_29222245","title":"Novel approaches to therapy in CML.","date":"2017","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/29222245","citation_count":22,"is_preprint":false},{"pmid":"33545036","id":"PMC_33545036","title":"TCR+/BCR+ dual-expressing cells and their associated public BCR clonotype are not enriched in type 1 diabetes.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33545036","citation_count":22,"is_preprint":false},{"pmid":"12476302","id":"PMC_12476302","title":"Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12476302","citation_count":21,"is_preprint":false},{"pmid":"25629972","id":"PMC_25629972","title":"Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25629972","citation_count":21,"is_preprint":false},{"pmid":"32586039","id":"PMC_32586039","title":"Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32586039","citation_count":20,"is_preprint":false},{"pmid":"30504306","id":"PMC_30504306","title":"Molecular monitoring in CML: how deep? How often? How should it influence therapy?","date":"2018","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/30504306","citation_count":20,"is_preprint":false},{"pmid":"35551036","id":"PMC_35551036","title":"The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.","date":"2022","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35551036","citation_count":19,"is_preprint":false},{"pmid":"38394773","id":"PMC_38394773","title":"Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors.","date":"2024","source":"Journal of the National Comprehensive Cancer Network : JNCCN","url":"https://pubmed.ncbi.nlm.nih.gov/38394773","citation_count":19,"is_preprint":false},{"pmid":"38066920","id":"PMC_38066920","title":"Resistance mutations in CML and how we approach them.","date":"2023","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/38066920","citation_count":18,"is_preprint":false},{"pmid":"19959082","id":"PMC_19959082","title":"Treatment strategies for CML.","date":"2009","source":"Best practice & research. Clinical haematology","url":"https://pubmed.ncbi.nlm.nih.gov/19959082","citation_count":18,"is_preprint":false},{"pmid":"12764362","id":"PMC_12764362","title":"Current CML therapy: progress and dilemma.","date":"2003","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/12764362","citation_count":18,"is_preprint":false},{"pmid":"26716419","id":"PMC_26716419","title":"FZD7 regulates BMSCs-mediated protection of CML cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26716419","citation_count":18,"is_preprint":false},{"pmid":"16849647","id":"PMC_16849647","title":"The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16849647","citation_count":18,"is_preprint":false},{"pmid":"21373837","id":"PMC_21373837","title":"In search of CML stem cells' deadly weakness.","date":"2011","source":"Current hematologic malignancy reports","url":"https://pubmed.ncbi.nlm.nih.gov/21373837","citation_count":17,"is_preprint":false},{"pmid":"36369657","id":"PMC_36369657","title":"Higher-order interactions of Bcr-Abl can broaden chronic myeloid leukemia (CML) drug repertoire.","date":"2023","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/36369657","citation_count":17,"is_preprint":false},{"pmid":"22054728","id":"PMC_22054728","title":"Hurdles toward a cure for CML: the CML stem cell.","date":"2011","source":"Hematology/oncology clinics of North America","url":"https://pubmed.ncbi.nlm.nih.gov/22054728","citation_count":17,"is_preprint":false},{"pmid":"26252834","id":"PMC_26252834","title":"Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts.","date":"2015","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26252834","citation_count":17,"is_preprint":false},{"pmid":"12543778","id":"PMC_12543778","title":"Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12543778","citation_count":16,"is_preprint":false},{"pmid":"21062245","id":"PMC_21062245","title":"Current treatment concepts of CML.","date":"2011","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/21062245","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44488,"output_tokens":5552,"usd":0.108372,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14099,"output_tokens":5996,"usd":0.110198,"stage2_stop_reason":"end_turn"},"total_usd":0.21857,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"The normal BCR gene encodes a 160,000-dalton phosphoprotein (designated PHL) with associated serine/threonine kinase activity, as demonstrated by expression studies and kinase assays in leukemic cells.\",\n      \"method\": \"Protein expression analysis and in vitro kinase assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro kinase assay with biochemical characterization of the purified protein product, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"3299055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"The BCR gene on chromosome 22 is fused in a head-to-tail fashion to the ABL oncogene as a consequence of the Philadelphia translocation, generating a chimeric BCR/ABL mRNA with 5' BCR and 3' ABL sequences that encodes an abnormal fusion protein.\",\n      \"method\": \"Molecular cloning, Southern blot, chimeric mRNA characterization\",\n      \"journal\": \"Bailliere's clinical haematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated across multiple labs using molecular cloning and transcript analysis; foundational structural finding about BCR-ABL fusion\",\n      \"pmids\": [\"3332859\", \"3859408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The BCR gene encodes a protein of 1271 amino acids; its transcripts (7.0 and 4.5 kb) are expressed in all cell types examined, and the first 902–927 amino acids of BCR are included within the CML-specific BCR-ABL chimeric mRNA.\",\n      \"method\": \"cDNA cloning, Northern blot, sequence analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cDNA cloning with full sequence characterization and transcript analysis; replicated by multiple groups\",\n      \"pmids\": [\"3285291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Both normal BCR protein products and the p210 BCR-ABL fusion protein are recovered predominantly from the cytosolic fraction, not the membrane fraction, as shown by subcellular fractionation and in vivo labeling experiments.\",\n      \"method\": \"Subcellular fractionation, in vivo radiolabeling, immunoprecipitation\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct subcellular fractionation with in vivo labeling; single lab but two orthogonal methods\",\n      \"pmids\": [\"2232885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"The P210 BCR-ABL protein does not transform NIH/3T3 fibroblasts (unlike v-abl), but a gag-BCR-ABL recombinant that adds myristylation-dependent membrane localization does transform fibroblasts, indicating that a membrane-targeting signal is required for fibroblast transformation by BCR-ABL.\",\n      \"method\": \"NIH/3T3 transformation assay, retroviral expression of BCR-ABL cDNA constructs\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct functional transformation assay with defined constructs, mechanistically informative negative result for BCR-ABL and positive result for gag-BCR-ABL\",\n      \"pmids\": [\"2440107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"BCR rearrangement and joint translocation of BCR and c-ABL sequences occur even in Ph1-negative CML patients, demonstrating that BCR-ABL fusion is the essential molecular event in CML regardless of Philadelphia chromosome visibility.\",\n      \"method\": \"Southern blot, molecular analysis of chromosomal rearrangements\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct molecular analysis demonstrating BCR-ABL rearrangement in Ph1-negative CML; confirmed independently\",\n      \"pmids\": [\"3859408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BCR acts as a negative regulator of the BCR-ABL oncoprotein: the BCR coiled-coil domain at its amino-terminus drives oligomerization (tetramerization) of BCR-ABL, which activates ABL tyrosine kinase. BCR-ABL autophosphorylation on tyrosines inactivates the serine/threonine kinase activity of BCR. Phosphoserine-BCR binds to the ABL SH2 domain and inhibits BCR-ABL tyrosine kinase; serine 354 of BCR is critical for this inhibition.\",\n      \"method\": \"Biochemical assays, mutagenesis (serine 354), co-immunoprecipitation, kinase assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase activity assays and mutagenesis from single lab with multiple biochemical readouts\",\n      \"pmids\": [\"12476302\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Bcr is a major inhibitor of cytoplasmic c-Abl: endogenous Bcr forms a complex with c-Abl in hematopoietic and insect cells, and overexpression of Bcr suppresses activated c-Abl tyrosine kinase activity and reverses oncogenic transformation induced by an Abl SH2 construct. Bcr and the Abl SH2 protein were found in a complex, and sequestration of Bcr by Abl SH2 releases c-Abl from inhibition.\",\n      \"method\": \"Co-immunoprecipitation, kinase assays, cell transformation assays, overexpression studies\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus functional transformation and kinase assays in single lab with multiple orthogonal methods\",\n      \"pmids\": [\"12543778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The BCR coiled-coil (CC) domain at the N-terminus controls BCR-ABL oligomerization. Molecular dynamics simulations combined with crystallography validation showed that a binary complex of the BCR CC domain serves as the basic unit; the small α1-helix forms interchain aromatic dimeric packing in binary assembly and contributes to dimer-dimer packing in the quaternary assembly, driving tetramerization essential for membrane clustering and MAPK signaling.\",\n      \"method\": \"Molecular dynamics simulations, crystallography (literature-validated), structural analysis\",\n      \"journal\": \"Protein science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — crystallography and MD simulations from single study; structural validation referenced from experimental literature but computational modeling is primary new contribution\",\n      \"pmids\": [\"36369657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"c-CBL binds directly to the SH2 domain of BCR-ABL only when c-CBL is tyrosine-phosphorylated; however, deletion of the SH2 domain did not fully abolish CBL-BCR-ABL complex formation, suggesting a secondary interaction site or indirect bridging via CRKL. CRKL (an SH2/SH3 adapter) can mediate complex formation between c-CBL and BCR-ABL.\",\n      \"method\": \"Co-immunoprecipitation, domain deletion mapping, pulldown assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding mapped to SH2 domain with deletion mutagenesis; reciprocal Co-IP experiments; single lab\",\n      \"pmids\": [\"9195915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BCR-ABL kinase activity (but not expression alone) is required for constitutive entry of primary myeloid CML cells into S phase independent of growth factors; the defect in growth factor-dependent cell cycle arrest is completely corrected by the ABL-specific inhibitor CGP 57148.\",\n      \"method\": \"Cell cycle analysis (flow cytometry), kinase inhibitor treatment, primary CML cell culture\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined cellular phenotype corrected by specific kinase inhibitor; primary cells used; single lab\",\n      \"pmids\": [\"9488616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BCR-ABL cooperates with NUP98/HOXA9 to cause blast crisis in a murine bone marrow transplantation model; the blast crisis phenotype depends on both BCR-ABL and NUP98/HOXA9 expression. Blast crisis tumors retain sensitivity to the ABL inhibitor STI571 in vitro and in vivo, confirming continued BCR-ABL kinase dependence.\",\n      \"method\": \"Murine bone marrow transplantation model, genetic epistasis, in vitro/in vivo STI571 treatment\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in murine model with both constructs, confirmed with kinase inhibitor; functional readout with defined phenotype\",\n      \"pmids\": [\"12032333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Bcr-Abl kinase inhibition by PD180970 blocks constitutive Stat5 DNA-binding activity and suppresses CML cell proliferation/induces apoptosis; dominant-negative Stat5 alone also induces apoptosis in K562 cells. Candidate Stat5 target genes including Bcl-x, Mcl-1, c-Myc, and cyclin D2 are downregulated after BCR-ABL kinase inhibition.\",\n      \"method\": \"Kinase inhibitor treatment, dominant-negative Stat5 expression via vaccinia virus vector, EMSA, Western blot, apoptosis assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (kinase inhibitor + dominant-negative + primary cells); single lab\",\n      \"pmids\": [\"12483533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"AHI-1 interacts with BCR-ABL and JAK2 to form an AHI-1–BCR-ABL–JAK2 protein complex in CML cells. Overexpression of AHI-1 sustains BCR-ABL and JAK2-STAT5 phosphorylation and reverses growth deficiencies from BCR-ABL down-regulation; RNAi suppression of AHI-1 reduces growth autonomy of CML stem/progenitor cells.\",\n      \"method\": \"Co-immunoprecipitation, RNAi knockdown, phosphorylation analysis, in vitro colony assays, in vivo leukemia model\",\n      \"journal\": \"Journal of Experimental Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP identifying complex, multiple orthogonal functional methods (RNAi, overexpression, in vivo), validated in primary CML cells\",\n      \"pmids\": [\"18936234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BCR-ABL is rapidly modified with K63-linked ubiquitin polymers upon treatment with the ubiquitin-cycle inhibitor WP1130 (which directly inhibits the deubiquitinase Usp9x), leading to BCR-ABL accumulation in aggresomes where it cannot conduct signal transduction, and inducing apoptosis in both imatinib-sensitive and -resistant CML cells.\",\n      \"method\": \"Ubiquitin linkage analysis, aggresome detection, kinase signaling assays, apoptosis assay, Usp9x deubiquitinase activity assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical characterization of ubiquitin modification type and functional consequence; single lab with multiple methods\",\n      \"pmids\": [\"21248063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MYC and its partner MAX bind to the BCR promoter (demonstrated by ChIP) and upregulate BCR and BCR/ABL1 at both transcriptional and protein levels; silencing MYC in BCR/ABL1-positive cell lines significantly downregulates BCR and BCR/ABL1 expression, decreasing proliferation and inducing cell death.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), MYC overexpression/silencing, luciferase reporter assay, Western blot\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP confirms direct binding, luciferase reporter validates promoter activity, functional knockdown; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"26179066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BCR and BCR/ABL1 are similarly downregulated during myeloid differentiation in healthy donors and in chronic-phase CML patients but not in blast crisis, suggesting BCR and BCR/ABL1 share a common transcriptional control mechanism that is disrupted in blast crisis (in trans deregulation of both BCR and BCR/ABL1 promoters).\",\n      \"method\": \"Gene expression analysis during myeloid differentiation, comparison across CML phases\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — expression analysis during differentiation without direct promoter or transcription factor binding experiments; single lab\",\n      \"pmids\": [\"20520635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BCR-ABL promotes expression of histidine decarboxylase (HDC) and synthesis of histamine in CML basophilic cells via the PI3-kinase signaling pathway; BCR-ABL tyrosine kinase inhibitors (imatinib, nilotinib) decreased HDC mRNA expression and histamine levels in BCR-ABL-transformed cells and primary CML cells.\",\n      \"method\": \"BCR-ABL expression in Ba/F3 cells, PI3K pathway inhibition, RT-PCR, histamine measurement, TKI treatment\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct BCR-ABL expression and PI3K pathway inhibition experiments with functional readout; single lab with multiple methods\",\n      \"pmids\": [\"16849647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IRF5 is expressed in CML cells where it interacts with BCR-ABL kinase, which induces IRF5 tyrosine phosphorylation and reduces its transcriptional activity; imatinib partially restores IRF5 transcriptional activity. A BCR-ABL consensus site mutant (IRF5 Y104F) still shows tyrosine phosphorylation, suggesting additional phosphorylation sites or downstream kinase involvement.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation analysis, site-directed mutagenesis (Y104F), transcriptional activity assay, imatinib treatment\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and mutagenesis with phosphorylation and functional transcription assays; single lab\",\n      \"pmids\": [\"24445143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BCR-ABL-mediated upregulation of PRAME leads to increased EZH2 binding to the TRAIL promoter and suppression of TRAIL expression in CML cells; knockdown of PRAME or EZH2 by RNA interference restores TRAIL expression and enhances imatinib sensitivity.\",\n      \"method\": \"RNAi knockdown of PRAME and EZH2, chromatin immunoprecipitation (EZH2 on TRAIL promoter), RT-PCR, Western blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi combined with ChIP demonstrating mechanistic pathway; single lab with multiple methods\",\n      \"pmids\": [\"20838376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PTEN is downregulated by BCR-ABL in leukemia stem cells in CML; PTEN deletion accelerates CML development while PTEN overexpression delays CML and B-ALL development, suppresses leukemia stem cells, and induces cell-cycle arrest. PTEN suppresses B-ALL through regulating its downstream gene Akt1.\",\n      \"method\": \"Mouse model of BCR-ABL-induced leukemia, conditional Pten deletion, PTEN overexpression, stem cell assays, cell-cycle analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function and overexpression in murine model with defined cellular phenotype and pathway placement (PTEN-Akt1 axis); single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"19965668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BCR-ABL kinase activity suppresses expression of Thanatos-associated protein 11 (THAP11) in CML cells; THAP11 inhibits c-Myc transcription and its restoration by Abl kinase inhibitors reduces c-Myc expression, cyclin D1, ODC, and increases p21Cip1, inhibiting CML cell proliferation.\",\n      \"method\": \"Abl kinase inhibitor treatment, siRNA depletion of BCR-ABL, THAP11 overexpression, colony forming assay, RT-PCR, Western blot\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional experiments (inhibitor, siRNA, overexpression) with defined molecular pathway; single lab\",\n      \"pmids\": [\"21400515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BCR-ABL protein can be selectively degraded via the N-end rule ubiquitin-proteasome pathway using single amino acid-based PROTACs; the degradation level can be adjusted by substituting different amino acids at the N-end rule recognition site, and a single PEG linker achieves the best proteolytic effect. This results in effective growth inhibition of BCR-ABL-expressing K562 cells in vitro and in a xenograft model in vivo.\",\n      \"method\": \"PROTAC-mediated protein degradation, in vitro cell proliferation assay, K562 xenograft mouse model, Western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical degradation assay with mutagenesis of N-end rule signal and in vivo validation; single lab with multiple methods\",\n      \"pmids\": [\"37392851\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCR encodes a cytosolic serine/threonine kinase whose N-terminal coiled-coil domain drives BCR-ABL oligomerization/tetramerization, thereby activating the ABL kinase; the BCR moiety is autophosphorylated on tyrosines by BCR-ABL (inactivating BCR's own kinase activity), while phosphoserine-BCR can bind back to the ABL SH2 domain and inhibit oncogenic kinase activity. BCR-ABL signals constitutively through STAT5, PI3K/AKT, RAS/MAPK, and JAK2 pathways; it forms protein complexes with partners including CBL (via SH2), CRKL, AHI-1, and JAK2; it suppresses TRAIL via PRAME/EZH2, drives histamine synthesis via PI3K/HDC, phosphorylates and inactivates IRF5, and suppresses THAP11 to upregulate c-Myc. BCR and BCR-ABL expression are both transcriptionally regulated by the MYC/MAX heterodimer binding to the BCR promoter, and BCR-ABL is subject to K63-linked ubiquitination and aggresomal sequestration that blocks its signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BCR encodes a ubiquitously expressed 160-kDa cytosolic phosphoprotein of 1271 amino acids that carries an intrinsic serine/threonine kinase activity [#0, #2, #3]. Its principal biomedical importance derives from the Philadelphia translocation, which fuses 5' BCR sequences (the first ~902–927 residues) to the 3' ABL oncogene to create the chimeric BCR-ABL mRNA and fusion oncoprotein that is the essential molecular event in chronic myeloid leukemia [#1, #2, #5]. Within the fusion, the BCR moiety supplies an N-terminal coiled-coil domain that drives oligomerization and tetramerization of BCR-ABL, constitutively activating the ABL tyrosine kinase and enabling membrane clustering and downstream MAPK signaling [#6, #8]. Reciprocally, normal BCR is a negative regulator of ABL: it forms a complex with c-Abl and, through phosphoserine-354, binds the ABL SH2 domain to inhibit kinase activity, while BCR-ABL-mediated tyrosine autophosphorylation inactivates BCR's own serine/threonine kinase [#6, #7]. The oncogenic kinase rewires hematopoietic cells, driving growth-factor-independent S-phase entry [#10] and signaling through STAT5 to sustain anti-apoptotic and proliferative targets including Bcl-x, Mcl-1, c-Myc and cyclin D2 [#12], through PI3K (with PTEN downregulation in leukemic stem cells) [#17, #20], and through partner complexes with CBL, CRKL, AHI-1 and JAK2 [#9, #13]. Downstream transcriptional reprogramming includes PRAME/EZH2-mediated TRAIL suppression, IRF5 tyrosine phosphorylation and inactivation, and THAP11 suppression that upregulates c-Myc [#18, #19, #21]. BCR-ABL expression is itself driven by MYC/MAX binding to the BCR promoter [#15], and the oncoprotein is subject to K63-linked ubiquitination and aggresomal sequestration as well as targeted degradation strategies that abolish its signaling [#14, #22].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Established that the normal BCR gene product is an enzyme, defining it as a 160-kDa phosphoprotein with intrinsic serine/threonine kinase activity rather than a passive structural protein.\",\n      \"evidence\": \"Protein expression analysis and in vitro kinase assay in leukemic cells\",\n      \"pmids\": [\"3299055\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrates of BCR's own kinase not identified\", \"Regulation of BCR kinase activity in normal cells unknown\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"Defined the molecular basis of CML by showing BCR is fused head-to-tail to ABL by the Philadelphia translocation, generating a chimeric mRNA and fusion protein.\",\n      \"evidence\": \"Molecular cloning, Southern blot and chimeric mRNA characterization\",\n      \"pmids\": [\"3332859\", \"3859408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which fusion activates ABL not yet defined at this stage\", \"Functional consequence of the BCR portion unresolved\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Provided the full protein coding sequence (1271 aa) and showed BCR is broadly expressed, while delimiting the BCR segment (first ~902–927 aa) retained in BCR-ABL.\",\n      \"evidence\": \"cDNA cloning, Northern blot and sequence analysis\",\n      \"pmids\": [\"3285291\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Domain function within the retained BCR segment not yet assigned\"]\n    },\n    {\n      \"year\": 1985,\n      \"claim\": \"Showed BCR-ABL fusion is the essential molecular lesion in CML even when the Philadelphia chromosome is cytogenetically invisible, establishing the fusion (not the visible chromosome) as the disease driver.\",\n      \"evidence\": \"Southern blot and molecular rearrangement analysis in Ph1-negative CML\",\n      \"pmids\": [\"3859408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address how the fusion transforms cells mechanistically\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Localized both normal BCR and p210 BCR-ABL to the cytosol, framing where the kinase activity is deployed.\",\n      \"evidence\": \"Subcellular fractionation with in vivo radiolabeling and immunoprecipitation\",\n      \"pmids\": [\"2232885\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address dynamic or signal-induced membrane recruitment\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"Demonstrated that membrane targeting is rate-limiting for fibroblast transformation, since p210 BCR-ABL fails to transform NIH/3T3 cells but a myristylated gag-BCR-ABL does.\",\n      \"evidence\": \"NIH/3T3 transformation assay with defined retroviral BCR-ABL constructs\",\n      \"pmids\": [\"2440107\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relevance of fibroblast assay to hematopoietic transformation unclear\", \"Did not define the activating role of BCR coiled-coil oligomerization\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Resolved the reciprocal regulatory relationship: the BCR coiled-coil drives tetramerization that activates ABL, while phosphoserine-354 BCR binds the ABL SH2 domain to inhibit the oncogenic kinase.\",\n      \"evidence\": \"Biochemical and kinase assays, Co-IP, and serine 354 mutagenesis\",\n      \"pmids\": [\"12476302\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab biochemistry without structural confirmation at this stage\", \"Stoichiometry and dynamics of activation versus inhibition not quantified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Established normal Bcr as a major endogenous inhibitor of cytoplasmic c-Abl, with Abl SH2 sequestering Bcr to release c-Abl from inhibition.\",\n      \"evidence\": \"Co-IP, kinase and transformation assays, overexpression in hematopoietic and insect cells\",\n      \"pmids\": [\"12543778\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological context where this regulation operates unclear\", \"Single-lab evidence\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined the structural logic of BCR coiled-coil assembly, identifying a binary unit and α1-helix aromatic packing that builds the tetramer required for membrane clustering and MAPK signaling.\",\n      \"evidence\": \"Molecular dynamics simulations with crystallographic validation and structural analysis\",\n      \"pmids\": [\"36369657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Primary contribution is computational modeling\", \"Direct functional test of individual packing residues in cells limited\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Mapped CBL recruitment to the BCR-ABL SH2 domain (phospho-dependent) and identified CRKL as a bridging adapter, building the BCR-ABL adaptor complex.\",\n      \"evidence\": \"Co-IP, domain deletion mapping and pulldown assays\",\n      \"pmids\": [\"9195915\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Secondary CBL interaction site not identified\", \"Functional output of the complex not measured here\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed BCR-ABL kinase activity, not mere expression, drives growth-factor-independent S-phase entry, confirming kinase function as the proliferative driver.\",\n      \"evidence\": \"Cell cycle flow cytometry with ABL inhibitor CGP 57148 in primary CML cells\",\n      \"pmids\": [\"9488616\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream effectors linking kinase to cell-cycle machinery not defined here\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Connected BCR-ABL kinase to constitutive STAT5 activation and identified anti-apoptotic/proliferative STAT5 targets, defining a core survival pathway.\",\n      \"evidence\": \"Kinase inhibitor and dominant-negative Stat5 expression, EMSA, apoptosis assays in K562\",\n      \"pmids\": [\"12483533\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect regulation of named targets not fully separated\", \"Single-lab data\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrated genetic cooperation between BCR-ABL and NUP98/HOXA9 in driving blast crisis while preserving BCR-ABL kinase dependence.\",\n      \"evidence\": \"Murine bone marrow transplantation with genetic epistasis and STI571 treatment\",\n      \"pmids\": [\"12032333\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of cooperation between the two oncogenes not resolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified a PI3K-dependent BCR-ABL output driving histidine decarboxylase expression and histamine synthesis in basophilic CML cells.\",\n      \"evidence\": \"BCR-ABL expression in Ba/F3, PI3K inhibition, RT-PCR, histamine measurement, TKI treatment\",\n      \"pmids\": [\"16849647\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcription factors linking PI3K to HDC not defined\", \"Single-lab evidence\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified AHI-1 as a scaffold forming an AHI-1–BCR-ABL–JAK2 complex that sustains BCR-ABL/JAK2-STAT5 phosphorylation and growth autonomy of CML stem/progenitor cells.\",\n      \"evidence\": \"Reciprocal Co-IP, RNAi, overexpression, colony assays and in vivo leukemia model\",\n      \"pmids\": [\"18936234\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the ternary complex unknown\", \"Whether AHI-1 acts on normal BCR not addressed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Placed BCR-ABL upstream of PTEN downregulation in leukemic stem cells, with PTEN acting via Akt1 to restrain leukemogenesis.\",\n      \"evidence\": \"Murine BCR-ABL leukemia model with conditional Pten deletion/overexpression and stem cell assays\",\n      \"pmids\": [\"19965668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which BCR-ABL represses PTEN not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Suggested BCR and BCR/ABL1 share a common transcriptional control that is downregulated during normal myeloid differentiation but deregulated in trans in blast crisis.\",\n      \"evidence\": \"Gene expression analysis across myeloid differentiation and CML phases\",\n      \"pmids\": [\"20520635\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No direct promoter or transcription factor binding experiments\", \"Correlative expression data only\", \"Single lab\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined a BCR-ABL–PRAME–EZH2 axis that epigenetically suppresses TRAIL, linking the oncogene to apoptosis resistance.\",\n      \"evidence\": \"RNAi of PRAME/EZH2, ChIP of EZH2 on TRAIL promoter, RT-PCR/Western\",\n      \"pmids\": [\"20838376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of PRAME upregulation by BCR-ABL unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed K63-linked ubiquitination (via Usp9x inhibition) drives BCR-ABL into aggresomes where it cannot signal, identifying a degradative vulnerability independent of imatinib resistance status.\",\n      \"evidence\": \"Ubiquitin linkage and aggresome analysis, signaling and apoptosis assays with WP1130\",\n      \"pmids\": [\"21248063\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous E3 ligase mediating K63 modification not identified\", \"Single-lab evidence\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established that BCR-ABL kinase suppresses THAP11 to relieve repression of c-Myc, driving proliferation via c-Myc/cyclin D1/ODC and reduced p21.\",\n      \"evidence\": \"Abl inhibitor, BCR-ABL siRNA, THAP11 overexpression, colony assays, RT-PCR/Western\",\n      \"pmids\": [\"21400515\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How kinase activity represses THAP11 not defined\", \"Single-lab evidence\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed BCR-ABL interacts with and tyrosine-phosphorylates IRF5 to reduce its transcriptional activity, with a Y104F mutant implying additional phosphosites.\",\n      \"evidence\": \"Co-IP, phosphorylation analysis, Y104F mutagenesis, transcription assays, imatinib treatment\",\n      \"pmids\": [\"24445143\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Additional phosphorylation sites not mapped\", \"Functional consequence of IRF5 inactivation in CML pathology incompletely defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified MYC/MAX as direct transcriptional drivers of BCR and BCR/ABL1 via promoter binding, creating a feed-forward loop with c-Myc as both upstream and downstream of the oncogene.\",\n      \"evidence\": \"ChIP, MYC overexpression/silencing, luciferase reporter, Western blot\",\n      \"pmids\": [\"26179066\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay with the proposed differentiation-linked control not integrated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated that BCR-ABL can be selectively eliminated via N-end rule ubiquitin-proteasome PROTACs, providing a tunable degradation strategy with in vivo efficacy.\",\n      \"evidence\": \"Single amino acid PROTACs with N-end rule mutagenesis, proliferation assays, K562 xenograft\",\n      \"pmids\": [\"37392851\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Selectivity over normal BCR not fully established\", \"Single-lab proof of concept\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The physiological function and substrates of normal BCR's serine/threonine kinase, and how its inhibitory regulation of c-Abl operates in healthy cells, remain undefined relative to the well-characterized oncogenic fusion.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No physiological BCR kinase substrate identified\", \"Normal cellular role of BCR distinct from its fusion partner role unclear\", \"Structure of full-length BCR not determined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 6, 18]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 7]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [12, 13, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 13, 17, 8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 5, 11]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [10, 20]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [15, 18, 19, 21]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [14, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ABL1\", \"CBL\", \"CRKL\", \"AHI1\", \"JAK2\", \"IRF5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}